Business
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
BOSTON & MONTREAL, December 02, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has selected detalimogene voraplasmid (also known as detalimogene and previously EG-70) to participate in the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program. Detalimogene is a novel, investigational, non-viral gene therapy for pati
About this update from Engene Therapeutics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/61c8dc0caa38d3041f95f6bb833bfaab"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MrGdBfWiON.PrcuF2mBOpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/61c8dc0caa38d3041f95f6bb833bfaab","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/7D.dVzYHL5RSeyc70jGxaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/61c8dc0caa38d3041f95f6bb833bfaab","width":1024,"height":512}},"lazy":false},{"type":"text","content":"enGene one of nine companies awarded CDRP per year","length":50,"tagName":"p","attribs":{}},{"type":"text","content":"Program aims to support CMC development of products with expedited clinical development timeframes and provide patients with earlier access to these products","length":157,"tagName":"p","attribs":{}},{"type":"text","content":"Detalimogene has already been manufactured at commercial scale, and CDRP provides additional FDA CMC interactions ahead of a potential BLA submission in 2H 2026","length":160,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON & MONTREAL, December 02, 2025--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has selected detalimogene voraplasmid (also known as detalimogene and previously EG-70) to participate in the Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program. Detalimogene is a novel, investigational, non-viral gene therapy for patients with high-risk, non-muscle invasive bladder cancer (NMIBC).","length":605,"tagName":"p"},{"type":"text","content":""Manufacturing readiness in drug development is often underappreciated. We have already scaled detalimogene manufacturing to commercial-level, and CDRP is expected to help ensure CMC readiness for filing and commercialization," said Ron Cooper, President and Chief Executive Officer. "Our progress on the manufacturing front is in sync with detalimogene clinical development, w...